Form 8-K - Current report:
SEC Accession No. 0001193125-25-045671
Filing Date
2025-03-04
Accepted
2025-03-04 16:45:42
Documents
13
Period of Report
2025-03-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d939383d8k.htm   iXBRL 8-K 24081
  Complete submission text file 0001193125-25-045671.txt   141682

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sage-20250303.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sage-20250303_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sage-20250303_pre.xml EX-101.PRE 10810
16 EXTRACTED XBRL INSTANCE DOCUMENT d939383d8k_htm.xml XML 3555
Mailing Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY CAMBRIDGE MA 02142 617-299-8380
Sage Therapeutics, Inc. (Filer) CIK: 0001597553 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36544 | Film No.: 25705561
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)